Cargando…
RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
Male osteoporosis is an increasingly recognized problem in aging men. A common cause of male osteoporosis is hypogonadism. Thousands of men with prostate cancer are treated with androgen deprivation therapy, a treatment that dramatically reduces serum testosterone and causes severe hypogonadism. Men...
Autores principales: | Morgans, Alicia K., Smith, Matthew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196262/ https://www.ncbi.nlm.nih.gov/pubmed/22013547 http://dx.doi.org/10.4061/2011/941310 |
Ejemplares similares
-
Role of RANKL inhibition in osteoporosis
por: McClung, Michael
Publicado: (2007) -
The Next Frontier in Sarcoma: Molecular Pathways and Associated Targeted Therapies
por: Kim, Ted, et al.
Publicado: (2023) -
Frontiers in hormone therapy for male infertility
por: Khourdaji, Iyad, et al.
Publicado: (2018) -
Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
por: Zhang, Ning, et al.
Publicado: (2020) -
Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis
por: Huang, Dane, et al.
Publicado: (2022)